Regulatory Takeda’s first-in-class narcolepsy drug claims FDA approval PharmaphorumTakeda's orexin agonist Orzeyful is the first drug approved in the US that can treat the "full range" of narcolepsy type 1 symptoms, says the FDA.NeuroscienceRead full story pharminent August 6, 2026 (Last updated: August 8, 2026) Pharmaphorum Takeda’s orexin agonist Orzeyful is the first drug approved in the US that can treat the “full range” of narcolepsy type 1 symptoms, says the FDA. Neuroscience Read full story Post navigation Previous: Eli Lilly Smashes Q2 Estimates, Raises 2026 Guidance to $85–$87B on GLP-1 SurgeNext: FDA Approves Moderna’s mFlusiva, the First mRNA-Based Seasonal Flu Vaccine Related Stories Regulatory Jazz secures FDA approval for Ziihera in advanced HER2+ GEA pharminent August 26, 2026 Regulatory Roche, Eli Lilly get FDA nod for new Alzheimer’s blood test pharminent August 25, 2026 Regulatory Expanded US Imaavy approval first ever for wAIHA pharminent August 25, 2026
